PetMed Express, Inc. (NASDAQ: PETS) Receives Consensus Recommendation of “Hold” from Analysts


PetMed Express, Inc. (NASDAQ: PETS – Get Rating) has been assigned an average recommendation of “Hold” from the six research firms that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $ 27.00.

PETS has been the subject of several research analyst reports. Morgan Stanley dropped their price objective on shares of PetMed Express from $ 25.00 to $ 21.00 and set an “underweight” rating for the company in a research report on Tuesday, January 25th. StockNews.com initiated coverage on shares of PetMed Express in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Zacks Investment Research cut shares of PetMed Express from a “hold” rating to a “sell” rating in a research report on Wednesday, May 4th. Finally, Sidoti upgraded shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $ 32.00 target price for the company in a research report on Thursday, January 20th.

NASDAQ: PETS opened at $ 20.19 on Friday. The firm has a 50-day moving average of $ 24.44 and a 200-day moving average of $ 25.87. PetMed Express has a 1 year low of $ 19.08 and a 1 year high of $ 46.67. The stock has a market capitalization of $ 423.57 million, a P / E ratio of 19.41 and a beta of 0.55.

PetMed Express (NASDAQ: PETS – Get Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported $ 0.30 earnings per share for the quarter, topping the consensus estimate of $ 0.27 by $ 0.03. PetMed Express had a net margin of 7.72% and a return on equity of 15.45%. The firm had revenue of $ 66.00 million during the quarter, compared to analysts’ expectations of $ 67.80 million. During the same quarter in the previous year, the company posted $ 0.34 EPS. On average, analysts anticipate that PetMed Express will post 1.04 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 27th. Shareholders of record on Friday, May 20th will be given a dividend of $ 0.30 per share. This represents a $ 1.20 annualized dividend and a dividend yield of 5.94%. The ex-dividend date is Thursday, May 19th. PetMed Express’s payout ratio is 115.39%.

Several hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its holdings in shares of PetMed Express by 1.4% in the 1st quarter. BlackRock Inc. now owns 3,337,821 shares of the company’s stock valued at $ 86,115,000 after buying an additional 47,018 shares during the period. Vanguard Group Inc. grew its holdings in shares of PetMed Express by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 1,437,207 shares of the company’s stock valued at $ 37,079,000 after buying an additional 31,037 shares during the period. State Street Corp grew its holdings in shares of PetMed Express by 2.3% in the 4th quarter. State Street Corp now owns 1,022,162 shares of the company’s stock valued at $ 25,820,000 after buying an additional 22,763 shares during the period. Renaissance Technologies LLC grew its holdings in shares of PetMed Express by 19.1% in the 1st quarter. Renaissance Technologies LLC now owns 972,784 shares of its stock valued at $ 25,098,000 after buying an additional 156,300 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in PetMed Express by 0.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 575,564 shares of the company’s stock worth $ 14,539,000 after purchasing an additional 4,991 shares during the period. 80.95% of the stock is owned by institutional investors.

About PetMed Express (Get Rating)

PetMed Express, Inc., together with its subsidiaries, doing business as 1-800-PetMeds, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart / blood pressure, and other specialty medications, as well as generic substitutes.

Featured Stories



Receive News & Ratings for PetMed Express Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for PetMed Express and related companies with MarketBeat.com’s FREE daily email newsletter.

.

Leave a Comment

Your email address will not be published.